VectivBio Company
VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care.
It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.
Investors
Headquarters:
Basel, Basel-Stadt, Switzerland, Europe
Founded Date:
2019-01-01
Industry:
Drug Discovery & Development
Employee Number:
11-50
Super Industry:
Biopharma & Life Science Tools
Investors:
Bpifrance, Novo Holdings, OrbiMed, TCG Crossover, Vivo Capital
Ipo Status:
delisted
Stock Symbol:
VECT
City:
Basel
Region:
Basel-Stadt
Country:
Switzerland
Founders:
Christian Meyer, Luca Santarelli